ERCP Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)

ERCP Market Trends and Growth Drivers

Minimally Invasive Procedures Are Biggest Market Trends

• The biggest trend in the ERCP market is minimally invasive diagnostic procedures.
• The biggest benefit of such procedures is their lower cost than traditional procedures. Moreover, in a minimally invasive endoscopy, the doctor, if required, will make a minute incision into the body to guide the endoscope inside.
• These smaller incisions mean less pain, scarring, and mental trauma, faster recovery, and a lower chance of complications compared to procedures that involve making a large cut on the skin and epidermis.
• Due to their lower complexity, they can be easily performed on an outpatient basis, which reduces the waiting times for patients.
• This can be critical for patients in urgent need of an ERCP, such as those with a perforated ulcer, bleeding in the bile duct, and pancreatic cancer.

Growing Incidence of Pancreatic and Bile Duct Disorders Drives Market

• The ERCP market is driven by the increasing number of people with problems in their bile ducts and pancreas.
• The most severe among them is pancreatic cancer, which, according to the World Cancer Research Fund International, accounted for over 510,990 cases in 2022.
• Additionally, it is the 12^th-most-common cancer in the world.
• The biggest risk factors for this condition are family history, chronic inflammation of the pancreas, tobacco smoking, diabetes, obesity, and certain genetic mutations.
• With 537 million diabetics and over 1 billion obese people around the world, pancreatic cancer is a significant issue, the burden of which will only increase.
• Another common disease that is diagnosed with an ERPC is gallstones, which affects up to 6% of the global population.
• Obesity and diabetes also contribute to gallstones, which is why as the incidence of these disorder rise, so will that of gallstones.
• Since ERCP is used for both diagnostic and therapeutic purposes in case of pancreatic cancer, gallstones, and other biliary tract and pancreatic issues, the market will continue to grow.

High Cost and Risk of Complications Hamper Market Growth

• The biggest restraints for the ERCP market are the high cost of the procedure and risk of complications with this procedure.
• Its high cost mainly stems from the fact that it combines a conventional endoscopy and a contrast X-ray.
• Depending on the provider, public or private, endoscopy can cost anywhere between USD 1,000 and USD 3,000.
• A contrast X-ray can cost up to USD 1,000 more.
• Thus, an ERCP, which combines these procedures, can cost up to USD up to USD 9,000.
• The costs could be even more without insurance, thus making it unaffordable for people in emerging economies and certain sections even in developed countries.
• Additionally, ERCP has several complications, including bleeding, infection, and inflammation, the very issues this procedure is designed to diagnose and treat.
• Therefore, extreme caution needs to be observed while performing it.
• Apart from the procedure itself, some people may be allergic to certain gases used for anesthetization.
• Resultingly, there are stringent safety regulations that need to be complied with, which calls for experts to perform this procedure.

ERCP Market Analysis

Product Analysis

Endotherapy devices hold the largest share in 2024, of ~40%. This is attributed to the increase in demand for ERCP devices coupled with the high incidence of pancreatitis, pancreatic cancer, gallbladder stones, and choledocholithiasis. As per the Pan American Health Organization, more than 60,000 people are estimated to have suffered from pancreatic cancer in 2022, and around 50,000 people will die from it, in the U.S.

Considering the importance of sphincterotomes in the market, prominent players have actively participated in the launch of various products, such as TRUEtome cannulating sphincterotome by Boston Scientific Corporation, CleverCut3V line of sphincterotomes by Olympus Corporation, and D.A.S.H Sphincterotome with DomeTip by Cook Group Incorporated, which has resulted in the high share of sphincterotome in the endotherapy devices market.

The endoscopes category will have the highest CAGR, of 8.53%, over the forecast period, due to the spur in cases of chronic biliary and GI diseases. As pe the Gastroenterology Journal, around 40% of the people in the world have a functional gastrointestinal disorder (FGID). In addition, companies are strenuously participating in the launch of various endoscopes, which is causing remunerative opportunities for the market. For instance, in January 2022, Cook Group Incorporated announced the launch of an endoscopic clipping device, Instinct Plus, in the U.S. This device provides firm clip retention and smooth handling with a duodenoscope for prophylactic clipping in the GI tract.

We have analyzed the following products:

• Endoscopes (Fastest-Growing Category)
• Endotherapy Devices (Largest Category)
  • Sphincterotome
  • Lithotripter
  • Stents
  • Cannulas
  • Forceps
  • Snares
  • Catheters
  • Guiding Wires
  • Balloons
  • Baskets
  • Others
• Visualization Systems
• Energy Devices
• Others

Application Analysis

Among all applications, the biliary sphincterotomy category accounts for the largest revenue share, of around 38%, in the endoscopic retrograde cholangiopancreatography market in 2024. This is on account of the high use of ERCP devices in the treatment of bile obstruction, common bile duct stones, tissue sampling, and stent placement. For instance, the incidence of intrahepatic bile duct cancer is around 10 per 100,000 men and women annually, in the U.S.

Pancreatic sphincterotomy is the fastest-growing category, with a CAGR of 8.67%. This is attributed to the rising number of people with issues in their GI tract that restrict the flow of bile and other enzymes to the small intestine from the pancreas. ERCP offers numerous benefits to people facing such issues, including pain and inflammation reduction.

These applications are covered in the report:

• Biliary Sphincterotomy (Largest Category)
• Biliary Dilatation
• Biliary Stenting
• Pancreatic Sphincterotomy (Fastest-Growing Category)
• Pancreatic Duct Dilatation
• Pancreatic Duct Stenting

End User Analysis

Hospitals & clinics are the largest end users of ERCP, and the category is expected to record the highest CAGR, of 8.26%, in the forecast period. This can be ascribed to the rising number of trained and accredited endoscopists, such as gastroenterologists or surgeons, a spur in the number of hospitals, and the majority of endoscopic diagnosis interventions performed in these healthcare facilities. Also, the same-day surgical care comprising both preventive and diagnostic procedures offered by various clinics drives the market growth in this category.

The segment is bifurcated as follows:

• Hospitals & Clinics ((Largest and Fastest-Growing Category)
• Ambulatory Surgery Centers
• Others

ERCP Market Geographical Outlook

• In 2024, the North American endoscopic retrograde cholangiopancreatography market accounts for the highest revenue share of around 35% in 2024.
• Around 3% of deaths in the U.S. occur due to pancreatic cancer every year.
• Moreover, the rising consumption of alcohol is leading to several diseases such as pancreatic neuroendocrine tumor (PanNET) and pancreatic adenocarcinoma.
• These factors are resulting in the high usage of ERCP procedures in the region.
• In addition, more than 20% of the Canadian population suffers from bile duct disease, which is further driving the market growth.
• The APAC market is expected to register the fastest growth, propelling at a CAGR of 8.72%, during the forecast period.
• This can be attributed to the increasing patient awareness regarding ERCP devices coupled with the rising prevalence of GERD and pancreatic cancer, in the region.
• Moreover, the surging government initiatives and awareness programs toward bile duct cancer, pancreatic conditions, and related complications are expected to propel the demand for ERCP devices in APAC.
• Japan and China dominate the regional market due to the high incidence of GI-related cancers in both countries.
• In Japan, pancreatic cancer is the fourth-leading cause of deaths among all cancers.

The report offers detailed analysis on the below-mentioned regions and countries:

• North America (Largest Regional Market)
  • U.S. (Larger and Faster-Growing Country Market)
  • Canada
• Europe
  • Germany (Largest and Fastest-Growing Country Market)
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • China (Largest Country Market)
  • India (Fastest-Growing Country Market)
  • Japan
  • Australia
  • South Korea
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest and Fastest-Growing Country Market)
  • Mexico
  • Rest of LATAM
• Middle East and Africa (MEA)
  • Saudi Arabia (Largest and Fastest-Growing Country Market)
  • South Africa
  • U.A.E.
  • Rest of MEA

ERCP Market Share

The ERCP market is consolidated because of the high entry barriers for new players. Being a medical procedure, devices for it require extensive R&D and production expertise, which increases operating expenses. Additionally, the regulatory process is long and complex, requiring high investments in clinical trials and documentation. The risk of non-approval of the devices is also high, which is why only established players operate in this field. This is also why major healthcare providers generally operate in long-term contracts with well-known medical device manufacturers who can offer product quality assurance.

ERCP Market News

• In August 2024, Fujifilm Holdings Corporation operationalized its NURA diagnostic center in Ulaanbaatar, which will focus on cancer screening.
• In August 2024, KARL STORZ SE & Co. KG entered into a partnership with Fujifilm Holdings Corporation to offer advance operating room solutions and flexible endoscopes for GI procedures.
• In April 2024, Olympus Corporation announced that it is developing AI models to advance endoscopy using the NVIDIA Inception program.
• In February 2024, HOYA Corporation announced the receipt of the CE mark for its new PENTAX Medical i20c video endoscope series.